Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPH-075 vs Keytruda in Malignant Neoplasms
NCT06307093Phase 1Completed
- Sponsor
- R-Pharm
- Start
- Mar 2023
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RPH-075 in melanoma, squamous cell carcinoma of the lung (SCCL) and head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by R-Pharm. Primary endpoints: Area under the curve concentration-time from 0 to 504 hours and Incidence of Adverse Reactions. Started Mar 2023; status: completed.
02
Drugs
RPH-075
03
Conditions
melanomasquamous cell carcinoma of the lung (SCCL)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06307093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06307093.